Iovance To Press Ahead With Melanoma Cell Therapy Filing Despite Doubters
Still Expects To File In 2022
Iovance has seen its share price collapse after releasing data from a second melanoma patient cohort – but is confident its potential first-in-class therapy is approvable.
You may also be interested in...
The long-delayed accelerated approval of the melanoma T-cell therapy comes a week early, and with a generous label.
The company is presenting an updated Phase II analysis at SITC as it prepares to complete its rolling BLA submission and readies its commercial launch.
A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.